Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
Hurley, M.N.; Cámara, Miguel; Smyth, Alan R.
Alan R. Smyth
Pseudomonas aeruginosa chronically infects patients with cystic fibrosis and is associated with greater morbidity. There has been limited progress on the clinical development of new antibiotics with novel modes of action. This review addresses some of the latest research developments on the exploitation of candidate adjuvant therapeutic agents that may act alongside conventional antibiotics as an alternative therapeutic strategy. After considering key mechanisms this opportunistic pathogen employs to control virulence, the progress of various strategies including the inhibition of quorum sensing, efflux pumps and lectins, and the use of iron chelators, bacteriophages, immunisation and immunotherapy is reviewed. Both therapeutic approaches in early development and clinical phase are discussed.
|Journal Article Type||Article|
|Publication Date||Oct 1, 2012|
|Journal||European Respiratory Journal|
|Publisher||European Respiratory Society|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Hurley, M., Cámara, M., & Smyth, A. R. (2012). Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. European Respiratory Journal, 40(4), doi:10.1183/09031936.00042012|
|Keywords||Antibiotic resistance, Antibiotic treatment, Cystic fibrosis and chronic infections, Pseudomonas|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc/4.0|
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc/4.0
You might also like
Antimicrobial resistance: Concerns of healthcare providers and people with CF
Preprint servers: a ‘rush to publish’ or ‘just in time delivery’ for science?